HOUSTON, Sept. 3, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company's management team will participate in two upcoming investor conferences this month.H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 10, 2025Time: 10 am ETFormat: Presentation by Arun Swaminathan, Ph ...

公司动态 - 公司取消股权信贷额度(ELOC) [1][3] - 公司将于2025年9月4日参加Renmark金融通信公司的虚拟非交易路演系列 讨论最新投资者演示 [2] - 演示将涵盖公司概述 加密货币资金库策略 潜在重大流动性事件以及ELOC取消等关键议题 [3] 管理层参与 - 董事长兼首席执行官Ted Karkus将主持投资者演示 [3] - 演示结束后将进行实时问答环节 [3] 活动详情 - 活动时间为2025年9月4日美国东部时间中午12点 [2] - 需通过指定链接注册参与 可能有名额限制 [3][4] - 活动回放将在公司投资者网站提供 [3] 公司业务概览 - 公司为新一代生物技术、基因组学和消费品企业 [5] - 业务涵盖全基因组测序解决方案 食管癌早期检测诊断技术开发 以及直接面向消费者的OTC膳食补充剂营销平台 [5] - 致力于通过创新和可操作的洞察构建更健康的世界 [5]

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025. An on-demand corporate presentation will be available here on September 5, 2025, a ...

BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time. Mr. Martin will be available throughout the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference vi ...

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- SOUTH SAN FRANCISCO, Calif., September 2, 2025 — Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that management will present at the H.C. Wainwright Global Investment Conference taking place September 8-10, 2025. Presentation Details:Date and Time: Monday, September 8 at 12:00 PM ETWebcast: Click Here A live webcas ...

SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 11:30 a.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About ApogeeApogee Therapeutics is a clinical-stage biotechnol ...

Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT) First-ever demonstration of therapeutically restored physiological serum AAT production in a Pi*ZZ individual during a non-drug related acute phase response (20.6 µM total AAT, 10.3 µM M-AAT) Single dose of 400 mg achieved 12.8 µM total AAT and 5.3 µM M-AAT; ongoing 400 mg multidose cohort has potential to deliver ...

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025, at 11:00 a.m. ET. The live webcast of the presentation will be available on the “Investors & Media” page under the “Event ...

公司近期活动 - 公司宣布将参加摩根士丹利第23届年度全球医疗保健会议 时间为2025年9月9日东部时间下午5:35 [1][3] - 公司宣布将参加H C Wainwright第27届年度全球投资会议 时间为2025年9月10日东部时间上午9:00 [1][3] - 炉边谈话和演示的网络直播将在公司网站活动与演示部分提供 直播回放将在活动结束后保留90天 [1] 公司业务概况 - 公司是临床阶段生物技术公司 专注于开发T细胞受体工程化T细胞疗法用于癌症治疗 [2] - 主要TCR-T候选疗法针对血液恶性肿瘤患者 用于预防异基因造血细胞移植后复发 目前处于ALLOHA Phase 1血液试验阶段 [2] - 公司开发并持续扩展ImmunoBank治疗性TCR库 可识别多样化靶点并关联多种HLA类型 为多种癌症患者提供定制化多重TCR-T疗法 目前处于PLEXI-T Phase 1实体瘤试验阶段 [2] - 公司目前正在为两个临床项目招募患者 [2] 行业会议参与 - 摩根士丹利会议地点位于纽约时代广场喜来登酒店 [3] - H C Wainwright会议地点位于纽约乐天皇宫酒店 [3]

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Altimmune class acti ...